蒽环类药物新辅助化疗原发性乳腺癌患者疗效的影响因素  

Influential factors of anthracycline neoadjuvant chemotherapy in the treatment of primary breast cancer

作　　者：董力[1] 郝广旭[1] 任毅[1] 

机构地区：[1]江苏省徐州市肿瘤医院乳腺科,徐州221005

出　　处：《中国肿瘤临床与康复》2015年第12期1409-1411,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨蒽环类药物新辅助化疗原发性乳腺癌患者疗效的影响因素。方法回顾性分析30例蒽环类药物新辅助化疗原发性乳腺癌患者的临床资料,采用Logistic回归分析患者达到病理完全缓解的影响因素。结果 30例原发性乳腺癌患者中,完全缓解占26.7%,部分缓解占53.3%,病情稳定占20.0%,疾病进展占0.0%,有效率为80.0%(24/30),病理完全缓解(p CR)占23.3%。单因素分析结果显示,肿瘤直径、淋巴结状态、孕激素受体以及雌激素受体表达为影响蒽环类药物新辅助化疗原发性乳腺癌患者p CR的因素;Logistic回归分析结果显示,肿瘤直径是蒽环类药物新辅助化疗原发性乳腺癌p CR的独立影响因素(P<0.05)。结论原发性乳腺癌患者应用蒽环类药物新辅助化疗疗效较好。肿瘤直径为影响蒽环类药物新辅助化疗原发性乳腺癌p CR的独立因素。Objective To explore the influential factors of anthracycline neoadjuvant chemotherapy in the treatment of primary breast cancer. Methods The clinical date of 30 patients with primary breast cancer and underwent anthracycline neoadjuvant chemotherapy were retrospectively analyzed. The influencing factors of patients with pathological complete response（ PCR） were analyzed by using Logistic regression analysis. Results Among 30 cases with primary breast cancer,complete response（ CR）,partial response（ PR）,stable disease（ SD）,progressive disease（ PD） rates were 26. 7%,53. 3%,20. 0%,0. 0% respectively. The overall response rate（ RR） was 80. 0%（ 24 /30）. The PCR was 23. 3%. Single factor analysis of variance showed that tumor size,lymph node status,expression of progesterone receptor（ PR） and estrogen receptor（ ER） were related factors for patients of primary breast cancer in the treatment of anthracycline neoadjuvant chemotherapy. Logistic regression analysis showed that tumor size was the independent impact factor of primary breast cancer with anthracycline neoadjuvant chemotherapy. Conclusions The anthracycline neoadjuvant chemotherapy for primary breast cancer have a good effect. The tumor size was the independent impact factor of primary breast cancer with anthracycline neoadjuvant chemotherapy.

关 键 词：乳腺肿瘤 蒽环类药物 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]